Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Novelix Pharmaceuticals live price: ₹53. It opened at ₹58 vs previous close ₹54; intraday high/low: ₹58/₹53. The 50 & 200 DMA stand at ₹55.54/₹50.26.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹53
  • Today's High
  • ₹58
  • 52 Week Low
  • ₹28
  • 52 Week High
  • ₹70
  • Open Price₹58
  • Previous Close₹54
  • Volume13,980
  • 50 DMA₹55.54
  • 100 DMA₹55.22
  • 200 DMA₹50.26

Novelix Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -5.05%
  • Over 3 Month -15.13%
  • Over 6 Month -12.56%
  • Over 1 Year + 89.69%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.1
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 93
  • P/B Ratio
  • 3.1
  • Average True Range
  • 4.23
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.37
  • RSI
  • 42.6
  • MFI
  • 80.18

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹53.00
-0.64 (-1.19%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹54.68
  • 50 Day
  • ₹55.54
  • 100 Day
  • ₹55.22
  • 200 Day
  • ₹50.26

Resistance and Support

54.75 Pivot Speed
  • R3 62.70
  • R2 60.55
  • R1 56.90
  • S1 51.10
  • S2 48.95
  • S3 45.30

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 127.97 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 81 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results

Novelix Pharmaceuticals Shareholding Pattern

49.43%
46.42%
4.15%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹53 As on 16 May, 2026 | 05:49

The Market Cap of Novelix Pharmaceuticals is ₹93.4 Cr As on 16 May, 2026 | 05:49

The P/E ratio of Novelix Pharmaceuticals is 51.1 As on 16 May, 2026 | 05:49

The PB ratio of Novelix Pharmaceuticals is 3.1 As on 16 May, 2026 | 05:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23